NCT00369434View on ClinicalTrials.gov

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

June 30, 2006

Study Completion Date

February 28, 2007

Conditions
MenopauseVasomotor System
Interventions
DRUG

Desvenlafaxine succinate sustained-release (DVS SR)

Trial Locations (34)

15090

Wexford

16502

Erie

19114

Philadelphia

20852

Rockville

23294

Richmond

23507

Norfolk

27103

Winston-Salem

29926

Hilton Head Island

30033

Decatur

31406

Savannah

33143

Miami

33606

Tampa

33709

St. Petersburg

34452

Inverness

34471

Ocala

34613

Brooksville

34652

New Port Richey

36106

Montgomery

40291

Louisville

58104

Fargo

58501

Bismarck

59102

Billings

66210

Overland Park

80910

Colorado Springs

83404

Idaho Falls

83702

Boise

84047

Midvale

85381

Peoria

87102

Albuquerque

89146

Las Vegas

91786

Upland

97401

Eugene

04102

Portland

45267-0457

Cincinnati

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00369434 - Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women | Biotech Hunter | Biotech Hunter